Astellas Pharma Canada named a Great Place to Work® for the fourth consecutive year
April 29, 2019
Astellas Pharma Canada, Inc. named to the 2019 List of Best Workplaces™ for Inclusion
January 15, 2019
Health Canada Approves XTANDI® (enzalutamide) - the First and Only Oral Treatment for Men with Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer
January 14, 2019


Astellas and the Movember Foundation Put Prostate Cancer First with #flashyourstache
November 21, 2018
Astellas Pharma Canada partners with Wish of a Lifetime Canada to fulfill the lifelong wishes of Canadian seniors
July 05, 2018
Astellas Oncology C3 Prize® Returns for Third Year with Focus on Improving Cancer Care in Underserved Regions of the World
June 12, 2018
Astellas Pharma Canada Scores a "Hat Trick" as a Great Place to Work®
April 26, 2018
Astellas Names Percival Barretto-Ko as President, Americas Operations
March 15, 2018
Phase 3 PROSPER Trial Shows XTANDI� (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer
February 6, 2018
Astellas Appoints Kenji Yasukawa as President and CEO
January 31, 2018
Astellas Announces Leadership Changes in Canada and U.S.
January 8, 2018


Astellas, the Movember Foundation and the Toronto Maple Leafs Enter a Power Play with #pucks4prostate
November 1, 2017
Astellas Pharma Canada Partners with the Abilities Centre for Eighth Annual Changing Tomorrow Day
October 25, 2017
$100,000 in Grant Funding Awarded to Support Transformative Thinking in Transplantation
September 27, 2017
The Canadian Society of Transplantation and Astellas Pharma Canada Announce the 2017 CST-Astellas T3 Competition
July 12, 2017
The Astellas Oncology C3 Prize Returns for a Second Year; Aims to Inspire and Support Innovative Ideas for Cancer Care with $100,000 in Grants
June 20, 2017
Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer
June 9, 2017
Astellas Grows Partnership with the Canadian National Transplant Research Program to Catalyze Innovative Research in Transplantation
June 1, 2017
Astellas Pharma Canada Recognized as a Great Place to Work® for Second Consecutive Year
April 27, 2017


Astellas Renews Commitment with CUA-CUOG to Advance Uro-oncology Research in Canada
December 2, 2016
Astellas and #Baskets4Bros Raise $50,000 for Movember with Toronto Raptors Fans
December 1, 2016
Astellas Extends Commitment with the Canadian Urological Association to Advance Research in Canada
November 18, 2016
Astellas Partners with the Quebec Urological Association Foundation to Advance Urology Research
November 10, 2016
Launch of Alberta Transplant Innovation Fund to Accelerate Transplant Research and Innovation in Canada
October 26, 2016
World Anti-Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports
October 14, 2016
Dr. Kathryn Tinckam Named as Recipient of Inaugural Astellas and Canadian Society of Transplantation Clinical Research Grant
October 13, 2016
Canadian Innovation in Fatigue-Reducing Light Therapy Among Global Winners of Astellas Oncology's C3 Prize™ to Change Cancer Care
October 11, 2016
Astellas Oncology Selects Five C3 Prize™ Finalists to Pitch Ideas for Changing Cancer Care to Panel Including Robert Herjavec at Stanford Medicine X
September 12, 2016
Astellas Pharma Canada Partners with Camp Trillium for Seventh Annual Changing Tomorrow Day
September 7, 2016
Astellas and World Transplant Games Federation Announce Launch of Fit for Life! to Promote Physical Activity in Transplant Recipients Worldwide
August 19, 2016
Astellas Employees Assemble to Benefit Metro Vancouver's Native Youth in Need
July 26, 2016
Astellas and the CNTRP Continue Partnership and Commitment to Canadian Research Innovation
April 27, 2016
Astellas Oncology C3 Prize to Bring Bright Ideas in Cancer Care to Life with $100,000 in Grants
April 26, 2016
Astellas Pharma Canada Named as a Great Place to Work
April 22, 2016
Astellas Announces Results of Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics and Changes to Subsidiaries
February 10, 2016
Astellas Names James Robinson President, Americas Operations
February 8, 2016


Astellas to Acquire Ocata Therapeutics, Inc.
November 10, 2015
Astellas Pharma Canada Announces Recipients of 2015 CUA-CUOG Astellas Research Grant Program
October 15, 2015
Astellas Pharma Canada Partners with Canadian Society of Transplantation
October 8, 2015
CUA Astellas Grant Provides Boost to Canadian Urology Research
October 5, 2015
Astellas Partners with GUMOC to Advance Genitourinary Oncology Research in Canada
June 29, 2015
Astellas Pharma Canada Partners with Camp Trillium for Sixth Annual Changing Tomorrow Day
May 27, 2015
Astellas and the Canadian National Transplant Research Program (CNTRP) Partner to Support Personalized Medicine Approaches to Improve Transplantation
May 6, 2015
Health Canada Approves New Indication for the Use of Xtandi� (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer
April 16, 2015


CUA Astellas Grant Provides Boost to Canadian Urology Research
September 12, 2014
Prostate Cancer Research Receives a Boost
September 4, 2014
Astellas Announces Health Canada�s Approval of Advagraf� as a Once-daily Immunosuppressive Therapy for Liver Transplant Patients
June 19, 2014
New England Journal of Medicine Publishes Results from Phase 3 PREVAIL Trial of Enzalutamide in Men with Chemotherapy-Na�ve Metastatic Prostate Cancer Progressing on Androgen Deprivation Therapy
June 2, 2014
CNTRP and Astellas launch Research Innovation Competition to support Transplant Research
April 23, 2014
Astellas partners with CUOG and CUA to advance uro-oncology research in Canada
February 12, 2014


Canadian urology research gains momentum: 2013 CUA Astellas grant recipients announced
August 29, 2013
Astellas Pharma Canada pledges additional funding in support of Canadian National Transplant Research Program
July 3, 2013
Notice to Hospitals - Health Canada Endorsed lmportant Safety lnformation on AmBisome
June 21, 2013
Astellas Introduces New Option for Men Living with Advanced Prostate Cancer
June 13, 2013
Janeway receives a new Starlight Fun Centre on behalf of Astellas to bring joy to children with serious illnesses
May 22, 2013
Astellas partners with CUOG to advance uro-oncology research in Canada
April 17, 2013
Astellas introduces Myrbetriq, a new class of treatment for Canadian patients with overactive bladder
April 10, 2013
There's a little Picasso in all of us: EASE announces the winners to its fourth annual "My Life with Eczema" art contest
March 19, 2013
Astellas Pharma Canada, Inc. receives a Notice of Compliance from Health Canada for Myrbetriq (mirabegron)
March 8, 2013


Urology research grant focused on improving patient care
December 12, 2012
For Men with Prostate Cancer, Sex Still Matters
November 29, 2012
Can Women Get Prostate Cancer? 34 per cent of Canadians confuse prostate cancer as a disease that can affect both men and women
September 17, 2012
Canadian urology research gets a boost
August 28, 2012
Canadian Urological Association Partners with Astellas Pharma Canada, Inc.
March 28, 2012
Young eczema sufferer wishes her disease away through art - and wins!
March 16, 2012
Medivation and Astellas Announce Positive Results from the Phase 3 AFFIRM Trial of MDV3100 in Prostate Cancer Patients Who Received Prior Chemotherapy
February 1, 2012
Astellas announces new Vice President of Sales and Marketing
January 26, 2012
Astellas and Theravance Announce Termination of License, Development and Commercialization Agreement for VIBATIV® (telavancin) for Injection
January 10, 2012


The Eczema Society of Canada and EASE invite kids to express disease through art
November 1, 2011
Lawsuit Against Sandoz For Patent Litigation In Canada
July 14, 2011
Starlight Children's Foundation™ to benefit from 'Astellas Aspire'
June 27, 2011
Astellas Assesses the Impact of the Tohoku Earthquake
March 15, 2011
Health Canada approves Protopic® (tacrolimus ointment) for the prevention of eczema flares.
February 17, 2011
Youngsters Illustrate What Eczema Feels Like Through Their Art
February 14, 2011


Astellas Pharma Canada Employees Participate in First Annual 'Changing Tomorrow Day'
October 19, 2010
Astellas Pharma Canada Appoints New President
June 29, 2010
Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
May 16, 2010
Astellas Research Competition Supports Canadian Investigators
April 8, 2010
Canadian Children Splash New Colours on Red, Itchy Skin
February 4, 2010


Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
December 18, 2009
Give Your Bladder a Hug This Month
November 23, 2009
Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
October 27, 2009
Famous Cartoonist Helps EASE Program Select the Next Pablo Picasso
September 29, 2009
Astellas Research Competition Supports Canadian Investigators
August 6, 2009
Simple blood test to identify organ rejection; Astellas Pharma Canada joins the PROOF Centre of Excellence to fund innovative research
July 23, 2009
Powder Room Gives its Summer Road Trip Seal of Approval
June 22, 2009
Canadians Set to Wear Yellow to Support Psoriasis Community
June 19, 2009
Solifenacin shows superior tolerability compared to oxybutynin immediate-release (IR)
April 30, 2009
Financial woes may worsen eczema symptoms
February 5, 2009


The Powder Room: Keeping In Better Shape Below The Belt
November 4, 2008
Psoriasis Support Canada Launches Awareness Campaign Called "Shed Your Threads"
October 3, 2008
Astellas Completes the New Buildings in its Tsukuba Research Center (Miyukigaoka)
October 1, 2008
Ease into Back-To-School: Program Helps Kids with Eczema Learn the ABCs of Managing Their Condition
August 28, 2008
Astellas Pharma Canada, Inc. Supports Bladder Care Centre at UBC Hospital
August 6, 2008
"Canada's Best Restrooms Honoured" - The Powder Room Seal Of Approval Awarded Nationwide
June 25, 2008
AdvagrafTM (Extended Release Tacrolimus) is Now Available In Canada for Kidney Transplant Patients
April 15, 2008
Canadians with Psoriasis Have Spoken and They Want More Support
April 10, 2008
Join The Search For Canada's Best Restrooms: Education Program Launches Cross-Canada Powder Room Map
March 6, 2008
Education is Key to Taking Control of Eczema: February is Eczema Awareness Month
February 6, 2008


Astellas Pharma announces the availability of Mycamine® in Canada
October 17, 2007
What Happens in The Powder Room, Stays in The Powder Room
October 2, 2007
Health Canada approves Astellas' Mycamine®
June 1, 2007


VesicareTM (Solefinacin Succinate) Now Available in Canada
November 16, 2006
Astellas to Acquire AMEVIVE®
April 3, 2006
Rub-A-Dub-Dub! Spend time in the tub!
April 3, 2006


Introducing "Penny's EGGS-im-ah"
September 12, 2005
It's a "three-peat" for Astellas Pharma Canada's Eczema Education Program
July 25, 2005
Yamanouchi, Fujisawa Unite to Form Astellas Pharma - Canadian operation based in Markham, Ontario
April 1, 2005
Fujisawa Canada donates two paediatric dermatology fellowships
February 28, 2005